<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chen Q</submitter><funding>Scientific Research Project of Tianjin Educational Committee</funding><funding>National Natural Science Foundation of China</funding><funding>State Key Laboratory of Bioactive Substance and Function of Natural Medicines</funding><funding>Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine</funding><pagination>5</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10770909</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>19(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The synthetic liver X receptor ligand (LXR) T0901317 (T0) has been reported to attenuate atherosclerosis (AS) without hyperglyceridemia due to innovative drug combination or nano-sized drug delivery. Given the key roles of mangiferin (MGF) in lipid metabolism and atherogenesis, it is critical to investigate progression of atherosclerotic lesion after combined treatment of MGF and T0.&lt;h4>Methods&lt;/h4>Atherosclerotic plaque formation and hepatic lipid accumulation were compared in Apoe&lt;sup>-/-&lt;/sup> mice among T0 and/or MGF treatment. The in vitro functions of MGF and T0 were analyzed by Oil-red O staining, cholesterol efflux assay, transmission electron microscopy and western blot analyses with or without acetylated low density lipoprotein.&lt;h4>Results&lt;/h4>The combination t</pubmed_abstract><journal>Chinese medicine</journal><pubmed_title>Combination of mangiferin and T0901317 targeting autophagy promotes cholesterol efflux from macrophage foam cell in atherosclerosis.</pubmed_title><pmcid>PMC10770909</pmcid><funding_grant_id>82304809</funding_grant_id><funding_grant_id>GTZK202208</funding_grant_id><funding_grant_id>2021KJ133</funding_grant_id><funding_grant_id>ZYYCXTD-C-202009</funding_grant_id><pubmed_authors>Chen Q</pubmed_authors><pubmed_authors>Liu M</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Wang D</pubmed_authors><pubmed_authors>Wang T</pubmed_authors><pubmed_authors>Bao R</pubmed_authors><pubmed_authors>Wu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Combination of mangiferin and T0901317 targeting autophagy promotes cholesterol efflux from macrophage foam cell in atherosclerosis.</name><description>&lt;h4>Background&lt;/h4>The synthetic liver X receptor ligand (LXR) T0901317 (T0) has been reported to attenuate atherosclerosis (AS) without hyperglyceridemia due to innovative drug combination or nano-sized drug delivery. Given the key roles of mangiferin (MGF) in lipid metabolism and atherogenesis, it is critical to investigate progression of atherosclerotic lesion after combined treatment of MGF and T0.&lt;h4>Methods&lt;/h4>Atherosclerotic plaque formation and hepatic lipid accumulation were compared in Apoe&lt;sup>-/-&lt;/sup> mice among T0 and/or MGF treatment. The in vitro functions of MGF and T0 were analyzed by Oil-red O staining, cholesterol efflux assay, transmission electron microscopy and western blot analyses with or without acetylated low density lipoprotein.&lt;h4>Results&lt;/h4>The combination t</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jan</publication><modification>2026-06-03T12:39:48.245Z</modification><creation>2025-02-19T05:00:21.827Z</creation></dates><accession>S-EPMC10770909</accession><cross_references><pubmed>38183139</pubmed><doi>10.1186/s13020-023-00876-9</doi></cross_references></HashMap>